Related Experiment Video
Updated: May 17, 2026

Assessing Energy Substrate Oxidation In Vitro with 14CO2 Trapping
Published on: March 23, 2022
Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism
Tara C Brennan-Speranza1, Holger Henneicke, Sylvia J Gasparini
1Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia. tara@anzac.edu.au
Abstract:
Long-term glucocorticoid treatment is associated with numerous adverse outcomes, including weight gain, insulin resistance, and diabetes; however, the pathogenesis of these side effects remains obscure. Glucocorticoids also suppress osteoblast function, including osteocalcin synthesis. Osteocalcin is an osteoblast-specific peptide that is reported to be involved in normal murine fuel metabolism. We now demonstrate that osteoblasts play a pivotal role in the pathogenesis of glucocorticoid-induced dysmetabolism. Osteoblast-targeted disruption of glucocorticoid signaling significantly attenuated the suppression of osteocalcin synthesis and prevented the development of insulin resistance, glucose intolerance, and abnormal weight gain in corticosterone-treated mice. Nearly identical effects were observed in glucocorticoid-treated animals following heterotopic (hepatic) expression of both carboxylated and uncarboxylated osteocalcin through gene therapy, which additionally led to a reduction in hepatic lipid deposition and improved phosphorylation of the insulin receptor. These data suggest that the effects of exogenous high-dose glucocorticoids on insulin target tissues and systemic energy metabolism are mediated, at least in part, through the skeleton.
Insights
Glucocorticoids disrupt metabolism by affecting the skeleton. Targeting osteoblasts or boosting osteocalcin levels can prevent these adverse effects, revealing a key role for bone in glucocorticoid-induced metabolic dysfunction.
Area of Science:
- Endocrinology
- Metabolic Science
- Bone Biology
Background:
- Long-term glucocorticoid use causes adverse metabolic effects like weight gain, insulin resistance, and diabetes.
- The mechanisms behind these side effects are not fully understood.
- Glucocorticoids inhibit osteoblast function and osteocalcin synthesis, a peptide involved in fuel metabolism.
Purpose of the Study:
- To investigate the role of osteoblasts and osteocalcin in the pathogenesis of glucocorticoid-induced metabolic dysfunction.
- To determine if skeletal manipulation can prevent or mitigate these adverse effects.
Main Methods:
- Osteoblast-specific disruption of glucocorticoid signaling in mice treated with corticosterone.
- Gene therapy to restore carboxylated and uncarboxylated osteocalcin levels in glucocorticoid-treated mice.
- Assessment of insulin resistance, glucose tolerance, weight gain, and hepatic lipid deposition.
Main Results:
- Disrupting glucocorticoid signaling in osteoblasts prevented insulin resistance, glucose intolerance, and weight gain in treated mice.
- Restoring osteocalcin levels via gene therapy mimicked these protective effects and reduced liver fat.
- Improved insulin receptor phosphorylation was observed with osteocalcin restoration.
Conclusions:
- Osteoblasts play a critical role in the development of glucocorticoid-induced metabolic disturbances.
- The skeleton, through osteocalcin, is a key mediator of glucocorticoid effects on systemic energy metabolism and insulin sensitivity.
Related Concept Videos
Regulation of Metabolism
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome II: Pathophysiology
